The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis.
Xin Hui S ChanIlsa Louisa HaeuslerYan Naung WinJames PikeBorimas HanboonkunupakarnMaryam HanafiahSue J LeeAbdoulaye A DjimdeCaterina I FanelloJean-René KiechelMarcus Vinícius Guimarães de LacerdaBernhards OgutuMarie A OnyambokoAndré Machado de SiqueiraElizabeth A AshleyWalter Robert John TaylorNicholas J WhitePublished in: PLoS medicine (2021)
While caution is advised in the use of amodiaquine in patients aged ≥12 years with concomitant use of heart rate-reducing medications, serious cardiac conduction disorders, or risk factors for torsade de pointes, there have been no serious cardiovascular events reported after amodiaquine in widespread use over 7 decades. Amodiaquine and structurally related antimalarials in the World Health Organization (WHO)-recommended dose regimens alone or in ACTs are safe for the treatment and prevention of malaria.
Keyphrases
- heart rate
- cardiovascular events
- systematic review
- end stage renal disease
- heart rate variability
- blood pressure
- coronary artery disease
- ejection fraction
- cardiovascular disease
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- drug induced
- left ventricular
- type diabetes
- meta analyses
- big data
- atrial fibrillation
- patient reported outcomes
- combination therapy
- smoking cessation